Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer - PubMed (original) (raw)
Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer
Kazumasa Takenaka et al. Eur J Cancer. 2004 Jul.
Abstract
The reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) was initially isolated as a transformation-suppressor gene by expression cloning and found to encode a membrane-anchored regulator of the matrix metalloproteinases (MMPs). Experimental studies have shown that RECK can suppress tumour - invasion, metastasis and angiogenesis. However, the clinical impact of RECK remains unclear. To assess the clinical significance of RECK-expression in non-small cell lung cancer (NSCLC), a total of 171 patients with completely resected pathological stage (p-stage) I-IIIA NSCLC were retrospectively examined. Expression of RECK and vascular endothelial growth factor (VEGF) in tumour tissues was assessed by immunohistochemical staining (IHS). Intratumoural microvessel density (IMVD), a measurement of angiogenesis, was also determined by IHS using an anti-CD34 antibody. A significant inverse correlation between RECK-expression and tumour angiogenesis was documented; the mean IMVD in tumours with strong RECK-expression (157.1) was significantly lower than that observed in tumours with weak RECK-expression (194.5; P = 0.008). Interestingly, this inverse correlation was seen only when VEGF was strongly expressed, which suggests that RECK could suppress the angiogenesis induced by VEGF. The 5-year survival rate for patients with tumours with strong RECK-expression (75.8%) was significantly higher than that for patients with weakly expressing tumours (54.3%; P = 0.016). Subset analyses showed that the prognostic impact of RECK-status was evident in patients with either adenocarcinoma, poorly differentiated tumours, or p-stage IIIA disease. A multivariate analysis confirmed that reduced RECK-expression was an independent and significant factor in predicting a poor prognosis (P = 0.009; Hazard ratio (HR), 0.474 with a 95% Confidence interval (CI) of 0.271-0.830). In conclusion, RECK-status is a significant prognostic factor correlated with tumour angiogenesis in NSCLC patients.
Similar articles
- Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Hasegawa S, Otake Y, Morioka Y, Takahashi C, Noda M, Ito H, Wada H, Tanaka F. Takenaka K, et al. Ann Surg Oncol. 2005 Oct;12(10):817-24. doi: 10.1245/ASO.2005.09.018. Epub 2005 Aug 8. Ann Surg Oncol. 2005. PMID: 16132376 - Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S, Moriuchi T. Takemoto N, et al. Lung Cancer. 2007 Dec;58(3):376-83. doi: 10.1016/j.lungcan.2007.07.004. Epub 2007 Aug 21. Lung Cancer. 2007. PMID: 17714826 - Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H. Tanaka F, et al. Cancer Res. 2002 Dec 1;62(23):7124-9. Cancer Res. 2002. PMID: 12460935 - RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.
Clark JC, Thomas DM, Choong PF, Dass CR. Clark JC, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):675-83. doi: 10.1007/s10555-007-9093-8. Cancer Metastasis Rev. 2007. PMID: 17828469 Review. - Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM, Camps C, Sirera R. Bremnes RM, et al. Lung Cancer. 2006 Feb;51(2):143-58. doi: 10.1016/j.lungcan.2005.09.005. Epub 2005 Dec 19. Lung Cancer. 2006. PMID: 16360975 Review.
Cited by
- RECK Gene Polymorphism is Associated with Susceptibility and Prognosis of Wilms' Tumor in Chinese Children.
Yu Y, Hu Y, Li K, Chen Z, Zhang H, Zhang L. Yu Y, et al. Med Sci Monit. 2015 Jul 3;21:1928-33. doi: 10.12659/MSM.893606. Med Sci Monit. 2015. PMID: 26141647 Free PMC article. - Metastasis suppressor genes.
Yan J, Yang Q, Huang Q. Yan J, et al. Histol Histopathol. 2013 Mar;28(3):285-92. doi: 10.14670/HH-28.285. Histol Histopathol. 2013. PMID: 23348381 Free PMC article. Review. - Expression of ADAMs and their inhibitors in sputum from patients with asthma.
Paulissen G, Rocks N, Quesada-Calvo F, Gosset P, Foidart JM, Noel A, Louis R, Cataldo DD. Paulissen G, et al. Mol Med. 2006 Jul-Aug;12(7-8):171-9. doi: 10.2119/2006–00028.Paulissen. Mol Med. 2006. PMID: 17088949 Free PMC article. - MicroRNA expression in lung tissues of asbestos-exposed mice: Upregulation of miR-21 and downregulation of tumor suppressor genes Pdcd4 and Reck.
Hiraku Y, Watanabe J, Kaneko A, Ichinose T, Murata M. Hiraku Y, et al. J Occup Health. 2021 Jan;63(1):e12282. doi: 10.1002/1348-9585.12282. J Occup Health. 2021. PMID: 34679210 Free PMC article. - miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer.
Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, Srougi M, Leite KR. Reis ST, et al. BMC Urol. 2012 May 29;12:14. doi: 10.1186/1471-2490-12-14. BMC Urol. 2012. PMID: 22642976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical